The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients

Lewis, Stephen J.; Potts, Lindsay; Barry, R. E.

doi:10.1016/s0163-4453(98)80008-x

Cited by 147 publications

(92 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No meta-analysis was performed because there was marked heterogeneity between the studies. We also identified 4 randomized, placebo-controlled trials of probiotic therapy for the prevention of antibiotic-associated diarrhea where prevention of CDAD was measured as a secondary outcome [19][20][21][22] ( Table 1; a longer version of this table is available online at www.cmaj.ca/cgi/content/full/1723/2/167/DC1). Study quality ranged from 3 to 5, with all the randomized studies being double-blinded.…”

Section: Resultsmentioning

confidence: 99%

Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review

Dendukuri

Costa²,

McGregor³

et al. 2005

Canadian Medical Association Journal

181

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review

Dendukuri

Costa²,

McGregor³

et al. 2005

Canadian Medical Association Journal

181

View full text Add to dashboard Cite

“…Recent meta-analyses reported a significant reduction of AAD cases when antibiotic therapy is associated with prior probiotic treatment [65][66][67]. Saccharomyces boulardii appears to be the most effective microorganism; however, LGG has also proven to be effective in children [68,69]. S. boulardii, for which there is a risk of hematogenous dissemination in immunocompromised patients, was effective in inhibiting the recurrence of episodes of Clostridium difficile infection [70].…”

Section: Antibiotic-associated Diarrheamentioning

confidence: 99%

Probiotics and health: An evidence-based review

Aureli

Capurso

Castellazzi

et al. 2011

Pharmacological Research

232

131

View full text Add to dashboard Cite

a b s t r a c tThe intestinal microbiota is an ecosystem formed by a variety of ecological niches, made of several bacterial species and a very large amount of strains. The microbiota is in close contact with the intestinal mucosa or epithelial interface which is, after the respiratory area, the largest surface of the body, occupying approximately 250-400 m 2 . The physiological activities of the microbiota are manifold and are just being unraveled. Based on the observations of the multiple roles played by the microbiota in health and disease, the notion of modifying it with appropriate formulations, i.e. probiotics, is being tested in several settings.This review summarizes the current knowledge on probiotics and discusses both limitations and acquired evidence to support their use in preventive and therapeutic medicine.

show abstract

“…Several clinical trials have been conducted using Saccharomyces boulardii for the prevention of AAD [30][31][32][33][34][35][36]. All but one concluded that S. boulardii was an effective agent for prevention of AAD [34].…”

Section: Antibiotic-associated Diarrheamentioning

confidence: 99%

“…Several randomized-controlled trials used Lactobacillus spp, Saccharomyces boulardii or a combination with C. difficile toxin acquisition and/or CDI as a primary or secondary outcome [45][46][47][48][49][50][51][52]. The trials had a small number of cases and short follow-up, the longest being 7 weeks by McFarland et al [45].…”

Section: Probiotics and Clostridium Difficile Infectionsmentioning

confidence: 99%

“…No patients in the probiotic group acquired CDI, whereas 9 out of 53 (17%) in the placebo group developed CDI (P=0.001). None of the remaining trials demonstrated a statistically significant decrease in CDI or C. difficile toxin acquisition with the use of probiotic therapy [45][46][47][48][49][50][51]. The above trials lacked adequate statistical power to determine the efficacy of probiotics.…”

Section: Probiotics and Clostridium Difficile Infectionsmentioning

confidence: 99%

See 1 more Smart Citation

Probiotics: Mechanisms of Action and Clinical Applications

Gogineni¹,

Morrow²,

Malesker³

2013

J Prob Health

View full text Add to dashboard Cite

Probiotics are living microorganisms which when taken in adequate amount provides benefit to the host. While this beneficial effect was originally thought to stem from improvements in the intestinal microbial balance, there is now substantial evidence that probiotics can also provide benefits by modulating immune functions. Extrapolation of immunomodulatory effects found in the laboratory and in animal studies with outcomes in human trials presents a difficult challenge. Not all probiotics are created equal and the benefits are strain and dose specific. With newer strain-specific clinical trials and meta-analysis of the clinical trials, the beneficial role of probiotics in certain diseases has been evolving. Some uncertainity still exists with probiotics in other diseases with regard to the therapeutic role, strain-specificity, dosage and duration. Identification of clinical characteristics of effective probiotic strains, their mechanisms of action and testing of probiotic-based treatment may provide the true beneficial effect of probiotics in various disorders.

show abstract

The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients

Cited by 147 publications

References 19 publications

Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review

Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review

Probiotics and health: An evidence-based review

Probiotics: Mechanisms of Action and Clinical Applications

Contact Info

Product

Resources

About